Novel treatment for cheilitis glandularis. by Bovenschen, H.J.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/81343
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
© 2009 The Authors. doi: 10.2340/00015555-0557
Journal Compilation © 2009 Acta Dermato-Venereologica. ISSN 0001-5555
Acta Derm Venereol 89
99Letters to the Editor 
Sir,
In 1870, von Volkmann (1) introduced the term chei-
litis glandularis (CG). He described a distinct, chronic 
inflammatory condition of the lower lip characterized 
by mucopurulent exudates from the ductal orifices of 
enlarged labial salivary glands. Historically, CG has 
been classified into three subtypes: simplex, superficial 
suppurative, and deep suppurative. However, it is now 
believed that these represent three stages in progression 
of a single disease entity. Conventional treatment consists 
of vermillionectomy or the administration of intralesional 
corticosteroids. Additional treatment with antibiotics is 
frequently necessary (2, 3). We report here on a patient 
with CG treated successfully with a combination of oral 
minocycline and tacrolimus ointment 0.1%, thereby 
avoiding invasive therapy. 
CASE REPORT
An otherwise healthy 58-year-old woman presented with 
a one-year history of persistent swelling of mainly the 
lower lip after considerable sunburn in summer (Fig. 1A). 
The main complaint was an intense burning pain that 
greatly impaired her quality of life. Anamnestically, there 
was no evidence for angioedema or urticaria. Dermato-
logical investigation revealed swollen, erythematous to 
purpuric lips with small firm indurated papules at the mar-
gin of the lips and mucosa. The lower lip was clinically 
more severe than the upper lip. There were no signs of 
bacterial superinfection or suppurative exudate. Cheilitis 
granulomatosa, lupus erythematosus, actinic cheilitis 
and sarcoidosis, amongst other dermatoses, had been 
ruled out by lip biopsy and auto-immune serology. The 
non-spectacular histology showed a normal epidermis 
with slight salivary gland enlargement, enlarged vessels 
and a dermal lymphohistiocytic infiltrate. No signs of 
suppurative exudate or bacterial infection were obser-
ved (Fig. 2). The diagnosis of CG simplex was made 
on clinicopathological correlation. Treatment consisted 
of minocycline 100 mg once daily in combination with 
topical tacrolimus ointment 0.1% twice daily, both for 6 
weeks. After 6 weeks both the clinical appearance and 
the burning pain had completely disappeared (Fig. 1B). 
The patient continued monotherapy with tacrolimus 
ointment 0.1% for another 6 weeks. A further 6-month 
treatment-free follow-up period did not reveal any sign 
of recurrence. No side-effects were recorded. 
DISCUSSION
It has been challenged that CG is a separate clinical 
entity or merely a reaction pattern to chronic irritation 
of the lips. It has been reported that CG is associated 
with various external causes, including actinic damage, 
factitial injury, atopy, infection, and tobacco irritation 
(4). CG is highly uncommon and has to be differentiated 
from other clinical entities, such as cheilitis granulo-
matosa, lupus erythematosus, angioedema, atopic 
cheilitis, actinic cheilitis and sarcoidosis. Diagnosis is 
made on clinicopathological correlation by excluding 
these differential diagnoses by lip biopsy derived histo-
logical analysis. 
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Fig. 1. Cheilitis glandularis simplex: 
(A) before and (B) after successful 
treatment with a combination of oral 
minocycline 100 mg once daily and 
tacrolimus ointment 0.1% twice daily 
for 6 weeks.
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The histopathology of CG can reveal a wide range of 
possible histological changes. Therefore, no regular or 
pathognomonic features of this disorder are observed 
at the microscopic level. Instead, a diverse collection of 
possible alterations can be detected in both epidermis 
and submucosal tissues. These findings best allow us to 
determine the aetiology and nature of individual cases. 
Although randomized controlled clinical trial are lacking 
due to the low incidence of CG, effective treatment 
often involves surgery or intralesional injections with 
corticosteroids (2, 3, 5). Topical corticosteroids, 5-fluor-
ouracil and cryotherapy are other described options, 
although the safety and efficacy of these treatments 
remain obscure (2, 4). There is only one case report 
describing a successful treatment of CG (secondary to 
oral lichen ruber planus) with topical calcineurin inhi-
bitors tacrolimus and pimecrolimus (4).
Minocycline has both anti-bacterial and anti-inflam-
matory actions, including suppression of neutrophil 
chemotaxis and proinflammatory cytokines, inhibition 
of T-cell activation and up-regulation of regulatory 
T-cell-associated interleukin 10 (6). Treatment with 
minocycline was preferable in our patient in order to 
establish an anti-inflammatory effect and meanwhile 
to prevent bacterial superinfection. The addition of 
tacrolimus ointment was based on the appearance of 
multiple T cells in the histology. Tacrolimus ointment 
is a strong T-cell inhibitor and acts by virtue of blocking 
calcineurin, an enzyme in T cells that is essential in their 
activation and the production of pro-inflammatory cyto-
kines. Many off-label indications have been described 
in the literature since the introduction of this type of 
medication for the treatment of atopic dermatitis (7).
It has been proposed that patients with CG have a 
slightly increased risk of development of dysplasia and 
malignant transformation of the lip (8). Therefore, it is 
important that patients are instructed to stop smoking 
and to reinstate proper hygiene. Furthermore, the use 
of sunscreens should be obligatory due to the reduced 
local immune surveillance caused by our treatment and 
therefore the theoretical chance of enhancing malignant 
transformation. In our patient the treatment period was 
short and during winter.
In conclusion, treatment of CG with a combination 
of oral minocycline and tacrolimus ointment 0.1% may 
be a novel option for those patients in whom invasive 
therapy is less preferable.
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Fig. 2. Non-specific histopathology of cheilitis glandularis simplex, in this case 
characterized by a dense lymphocytic infiltrate and enlarged salivary glands. 
Other differential diagnoses could be excluded. Magnification × 100.
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